profit from every $100 of sales.
$0$100
KalVista Pharmaceuticals
We have no price for KalVista Pharmaceuticals since 12 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$27.00+0.00% today
+134.8% since Oct 10, 25
1-year low $10.761-year high $27.00
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What KalVista Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$183 million of profit last year.
SalesProfit
KalVista Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| KalVista Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads KalVista Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -81 | -95 | -132 | -183 | |
| -81 | -94 | -126 | -173 | |
| -82 | -93 | -127 | -183 | |
| -3.36 | -3.33 | -3.44 | -3.69 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | – | 183 | 235 | 251 |
| Cash | – | 56 | 32 | 132 |
| Total debt | – | 8 | 7 | 6 |
| Total liabilities | – | 22 | 29 | 155 |
| – | 161 | 207 | 95 | |
| 24 | 28 | 37 | 50 | |
| – | -44.4% | -46.8% | -135.4% | |
| – | -57.7% | -61.3% | -192.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -78 | -75 | -89 | -153 | |
| 1 | 1 | 0 | 1 | |
| -79 | -76 | -90 | -154 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 10 | 22 | 12 |
Valuation
- –
- –
- –
- -499.0×
- 19.5×
- –
- –
- -5.8%
- -11.4%
- 0.0%
Profitability
- 92.0%
- -120.8%
- -119.4%
- -112.5%
- -46.8%
- -89.5%
- -1,057.4%
- -41.3%
- -50.4%
- 41.8%
Growth
- –
- –
- +45.7%
- –
- +20.1%
Financial health
- -0.4×
- -104.83
- 84.7%
- -6.2×
- 5.58
- 5.52
- 0.35
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 8%of 952
Bottom 3%of 884
Bottom 16%of 987
What analysts expect
- Average price target
- $28.50
- Range
- $27.00 – $32.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.92 | -0.38 | −144.5% |
| Mar 24, 2026 | -1.01 | -0.54 | −87.0% |
| Nov 10, 2025 | -0.92 | -0.96 | +4.2% |
| Sep 11, 2025 | -1.12 | -0.91 | −23.1% |
| Jul 10, 2025 | -0.99 | -0.80 | −23.9% |
| Mar 12, 2025 | -0.92 | -0.89 | −3.4% |
| Dec 5, 2024 | -0.91 | -0.91 | +0.0% |
| Sep 5, 2024 | -0.87 | -0.95 | +8.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
45No pass
Philip Fisher
44No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
33No pass
Terry Smith
27No pass
Questions about KalVista Pharmaceuticals
Is KalVista Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the KalVista Pharmaceuticals AI analysis
What does KalVista Pharmaceuticals do?
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. It is in Biotechnology.
Does KalVista Pharmaceuticals pay a dividend?
No. KalVista Pharmaceuticals does not pay a dividend at the moment.
Is KalVista Pharmaceuticals stock halal?
Yes. KalVista Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0.4% of its market value, under the 30% limit. How we check
Who are KalVista Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with KalVista Pharmaceuticals's.
Prices: daily closes to Jun 12, 2026. Fundamentals: company reports via invest-like data.